Carcinoma of the Cervix - Postgraduate Level

1. EPIDEMIOLOGY AND RISK FACTORS

• Young age at first intercourse (< 16 years)
• Multiple sexual partners
• Cigarette smoking
• Race/ethnicity
• High parity
• Low socioeconomic status
• Chronic immune suppression (including HIV/AIDS - cervical cancer is an AIDS-defining illness)
• HPV infection (the fundamental causal agent)
• Berek & Novak's Gynecology, p. 2217

2. PATHOGENESIS - HPV AND MOLECULAR MECHANISMS

• HPV E6 protein binds and degrades p53 tumor suppressor → prevents cell cycle arrest and apoptosis when damaged DNA is present
• HPV E7 protein binds and inactivates Rb (retinoblastoma protein) → disrupts transcription factor E2F → unregulated cellular proliferation
• Both steps are required for malignant transformation of cervical epithelial cells
• Cofactors include herpes simplex virus and Chlamydia trachomatis

• Berek & Novak's Gynecology, p. 2217-2218

3. PATHOLOGY

3.1 Histologic Types

3.2 Histologic Appearance of Early Invasion

• Abundant pink cytoplasm
• Hyperchromatic nuclei
• Small-to-medium nucleoli
• Tongue-like processes into the stroma
• Desmoplasia (fibroblast proliferation) in stroma
• Band-like infiltrate of chronic inflammatory cells

• Berek & Novak's Gynecology, p. 2222

4. CLINICAL FEATURES

4.1 Symptoms

• Abnormal vaginal bleeding - the most common presenting symptom; post-coital, intermenstrual, or postmenopausal bleeding
• Watery, blood-tinged vaginal discharge (may be malodorous with necrosis)
• Pelvic or back pain - indicates advanced disease with parametrial or pelvic sidewall involvement
• Leg edema - lymphatic or venous obstruction from pelvic disease
• Urinary symptoms - hematuria, frequency, or obstruction (advanced disease)
• Rectal symptoms - tenesmus, hematochezia (advanced disease)
• Early-stage disease may be completely asymptomatic, found only on routine screening

4.2 Colposcopic Appearance

• Atypical vessels: punctation, mosaic pattern, coarse irregular vessels are characteristic
• Irregular surface contour: ulceration (loss of desmosomes), papillary growth pattern
• Color change: yellow-orange rather than the normal pink squamous or red endocervical epithelium; due to increased vascularity, surface necrosis, or keratin production
• All papillary cervical growths must be biopsied to exclude invasive disease

5. STAGING - FIGO 2018 (REVISED)

FIGO 2018 Staging Table

• New IB substages (IB1, IB2, IB3)
• Stage IIIC introduced for lymph node metastasis regardless of primary tumor size
• Allowance of imaging and pathology to upstage
• Hydronephrosis alone (even without pelvic wall involvement) still constitutes Stage IIIB unless due to another cause
• Berek & Novak's Gynecology, p. 2225-2229 (Bhatla N, Berek JS et al. FIGO 2019)

6. IMAGING AND STAGING WORKUP

• Berek & Novak's Gynecology, p. 2225-2226

7. PROGNOSTIC FACTORS

7.1 Intermediate-Risk Factors (after radical hysterectomy)

1. Large tumor size
2. Deep cervical stromal invasion (middle or deep one-third)
3. Lymphovascular space invasion (LVSI)

7.2 High-Risk Factors

1. Positive or close surgical margins
2. Positive lymph nodes
3. Microscopic parametrial involvement

7.3 Survival by Factor

• Berek & Novak's Gynecology, p. 2251-2252

8. MANAGEMENT BY STAGE

Management Table (Berek & Novak Table 38-4)

8.1 Stage IA1 (< 3 mm, no LVSI)

• Less than 1% incidence of pelvic lymph node metastasis
• Therapeutic conization is adequate if fertility preservation desired; margins and post-conization ECC must be negative
• Extrafascial hysterectomy without lymphadenectomy for women who don't desire fertility
• If LVSI is present: modified radical hysterectomy + pelvic lymphadenectomy

8.2 Stage IA2 (3-5 mm invasion)

• Pelvic node metastasis rate: 3-8% → lymphadenectomy or SLN mapping required
• Modified radical hysterectomy (Type II) with pelvic LND
• Radical trachelectomy if fertility preservation desired

8.3 Stages IB1-IIA1 (small operable)

• Type III Radical (Wertheim) Hysterectomy + bilateral pelvic lymphadenectomy is standard
• Radical trachelectomy for fertility preservation in tumors ≤2 cm
• Chemoradiation is equally effective - equivalent OS but different morbidity profiles
• Adjuvant therapy indicated after surgery if intermediate or high-risk pathologic factors found

8.4 Locally Advanced (IB3, IIA2, IIB-IVA)

• Concurrent cisplatin-based chemoradiation is the standard of care
• Cisplatin 40 mg/m² weekly during external beam radiation
• External beam pelvic radiation (45-50 Gy) + intracavitary brachytherapy boost
• Para-aortic extended field radiation for IIIC2 disease

8.5 Barrel-Shaped Cervix (>6 cm)

• 17.5% central failure rate with radiation alone
• Option: External radiation (4000 cGy) + single intracavitary treatment → extrafascial hysterectomy 2-3 months later
• Central failure rate with combined approach: ~2%
• Berek & Novak's Gynecology, p. 2266-2272

9. RADICAL HYSTERECTOMY - SURGICAL ANATOMY

• Removal of uterus, upper third of vagina, parametria, and uterosacral ligaments
• Bilateral pelvic lymphadenectomy (obturator, external iliac, internal iliac, common iliac)
• Development of paravesical and pararectal spaces:
  • Paravesical space - bordered by obliterated umbilical artery medially, obturator internus laterally, cardinal ligament posteriorly, pubic symphysis anteriorly
  • Pararectal space - bordered by rectum medially, cardinal ligament anteriorly, hypogastric artery laterally, sacrum posteriorly
• Ureteral dissection out of the vesicouterine ligament tunnel ("unroofing the ureter")
• Mobilization of bladder off the upper third of the vagina (critical early step)

10. SPECIAL CLINICAL SITUATIONS

10.1 Cervical Cancer During Pregnancy

• Management depends on gestational age and stage at diagnosis
• Early-stage disease (IA-IB1) in first/second trimester: may delay treatment to achieve fetal viability
• Radical hysterectomy can be performed during pregnancy
• Late second trimester or third trimester: delay treatment until fetal maturity, then classical cesarean section + radical hysterectomy

10.2 Cancer of the Cervical Stump (after supracervical hysterectomy)

• Rare; diagnosis and treatment are more complex due to altered anatomy
• Radiation therapy is preferred; surgery is technically difficult
• 5-year survival rates are similar to intact uterus cases when matched by stage

10.3 Barrel-Shaped Cervix

• As described in section 8.5 - combined chemoradiation + adjuvant extrafascial hysterectomy considered

10.4 Cervical Carcinoma After Extrafascial Hysterectomy

• Incidental finding after simple hysterectomy for presumed benign disease
• Management depends on stage: radiation or chemoradiation is usually required
• Survival after radiotherapy: 95-100% for microscopic disease, 82-84% for macroscopic disease with free margins, 20-47% with obvious residual cancer

11. RECURRENT CERVICAL CANCER

11.1 Site-Based Treatment

• Post-surgery recurrence → radiation therapy (external ± intracavitary); 25% 5-year survival
• Post-radiation central recurrence → surgical therapy (pelvic exenteration) is preferred curative option

11.2 Pelvic Exenteration

1. Anterior exenteration - removal of bladder, vagina, cervix, uterus
2. Posterior exenteration - removal of rectum, vagina, cervix, uterus
3. Total exenteration - removal of bladder + rectum + vagina + cervix + uterus (supralevator spares rectum; infralevator includes perineum)

• Unilateral leg edema
• Sciatic pain
• Ureteral obstruction These suggest pelvic sidewall fixation and are contraindications to exenteration.

11.3 Chemotherapy for Recurrent Disease

• Berek & Novak's Gynecology, p. 2275-2278

12. ACUTE COMPLICATIONS AND EMERGENCIES

12.1 Acute Hemorrhage

• Biopsy to confirm neoplasia
• Vaginal pack with Monsel's solution (ferric subsulfate)
• External radiation therapy: 8-10 daily fractions at 180-200 cGy/day
• Broad-spectrum antibiotics to reduce infection
• Vascular embolization under fluoroscopy if severe

12.2 Ureteral Obstruction

• Bilateral obstruction with uremia: place percutaneous or transvesical ureteral catheters, then chemoradiation with curative intent
• Metastatic disease: stenting + palliative measures; median survival ~17 months with aggressive management

13. NEW UPDATES (2024-2025)

13.1 Immunotherapy - Major Paradigm Shift

• Pembrolizumab + chemotherapy ± bevacizumab significantly improved OS and PFS vs. chemotherapy ± bevacizumab in patients with PD-L1 CPS ≥1
• Now a standard first-line option for recurrent/metastatic disease
• [PMID: 38095881 - JAMA Oncol 2024]

• Pembrolizumab added to chemoradiation then continued as maintenance
• Phase III RCT in high-risk locally advanced cervical cancer (stages IIB-IVA, or IB2-IIA2 with node involvement)
• Significant improvement in PFS (HR 0.70, p=0.0020) reported in the Lancet 2024
• Overall survival benefit confirmed in updated Lancet Oct 2024 analysis [PMID: 39288779]
• This represents a major change from prior standard of care (cisplatin-chemoradiation alone)

• Cemiplimab vs. investigator's choice chemotherapy in recurrent disease
• Final OS analysis (2025): cemiplimab showed survival benefit in PD-L1+ tumors
• [PMID: 39798514 - Eur J Cancer 2025]

13.2 Sentinel Lymph Node Mapping

• Increasingly incorporated into management of early-stage (IA2-IB2) cervical cancer
• Technique: cervical injection of radiotracer and/or blue dye; sentinel nodes mapped bilaterally
• Can identify unexpected nodal drainage patterns
• Pathologic ultrastaging of sentinel nodes (serial sectioning + IHC) detects micrometastases missed by standard sectioning
• Recommended as alternative to full pelvic lymphadenectomy in selected cases (reflected in Berek & Novak Table 38-4)

13.3 Fertility-Sparing Surgery Updates

• Radical trachelectomy (vaginal or abdominal) is standard for IB1 tumors ≤2 cm
• Simple trachelectomy may be adequate for tumors < 2 cm with favorable features (ongoing trials)
• Neoadjuvant chemotherapy followed by fertility-sparing surgery is investigational

13.4 Bevacizumab in First-Line (LACC)

• GOG 240 established bevacizumab + cisplatin + paclitaxel as standard for recurrent/metastatic disease - confirmed in 2024 KEYNOTE-826 subanalysis

13.5 HPV Vaccination - Updated Evidence

• A 2025 Cochrane network meta-analysis (PMID: 41276263) confirmed HPV vaccination efficacy for cervical cancer prevention across 9-valent, quadrivalent, and bivalent vaccines
• 9-valent vaccine (Gardasil-9) is the current preferred vaccine in most countries
• WHO recommends a single-dose schedule for girls aged 9-14 years as an alternative to the 2-dose schedule (updated 2022/2024 guidance)

14. FOLLOW-UP AFTER PRIMARY TREATMENT

• Years 1-2: Every 3-4 months clinical examination
• Years 3-5: Every 6 months
• After 5 years: Annually
• Pap smear/vaginal vault cytology at each visit (sensitivity limited after radiation)
• CT or PET/CT for suspected recurrence
• MRI preferred for local recurrence assessment
• Most recurrences occur within 2 years (>80%)

SUMMARY TABLE - KEY NUMBERS

• Berek JS, Hacker NF. Berek & Novak's Gynecology, 16th ed. Chapter 38: Cervical Cancer. Wolters Kluwer. (p. 2217-2280)
• Bhatla N, Berek JS, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynecol Obstet 2019.
• Lorusso D et al. KEYNOTE-A18/ENGOT-cx11/GOG-3047. Lancet 2024 [PMID: 38521086, 39288779]
• Tewari KS et al. KEYNOTE-826 subgroup analyses. JAMA Oncol 2024 [PMID: 38095881]
• Oaknin A et al. EMPOWER-Cervical 1 final OS. Eur J Cancer 2025 [PMID: 39798514]
• Bergman H et al. HPV vaccination Cochrane network meta-analysis. Cochrane Database Syst Rev 2025 [PMID: 41276263]